Medications News

Twitter

Have a pet with #diabetes? We now carry Lantus Insulin. More about this product: bit.ly/2o5cqMr

test Twitter Media - Have a pet with #diabetes? We now carry Lantus Insulin. More about this product: https://t.co/Np4VnYichq https://t.co/rWr981AuEh

Mylan says IPR instituted on Sanofi Lantus patents ipstrategynews.com/2017/12/14/myl…

Mylan (MYL) Says PTAB Institutes Inter Partes Review Against ... - StreetInsider.com dlvr.it/Q5zb7w

tinyurl.com/y7796g5l Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus Patents

RT @Diabetes_Sanofi #GoForTheGoals, like better understanding why your diabetes can change. Watch this short video to learn more: bit.ly/2AFjPYB

test Twitter Media - RT @Diabetes_Sanofi #GoForTheGoals, like better understanding why your diabetes can change. Watch this short video to learn more: https://t.co/sDHgHd28i6 https://t.co/lj7if7Vo3H

Appeal board to review Sanofi’s Lantus insulin injection patents s.einnews.com/GpmL6FAssV

Erika and I were in our early stages when I found out I had type 1 and when my sugar was high, we didn’t know better and we thought giving me a bunch of LANTUS was a good idea... it wasn’t 😆 #type1probs 💉

Challenge of two Lantus patents commences seekingalpha.com/news/3318278-c… $SNY $MYL

Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - Markets Insider dlvr.it/Q5x5hs

test Twitter Media - Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - Markets Insider https://t.co/7RbWca8GJs https://t.co/szBaXag65c

Mylan announces the U.S. Patent and Trademark Appeal Board institutes inter partes review proceedings on all claims against Sanofi's Lantus® patents bit.ly/2yt2IU8 $MYL

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Cla.. financialbuzz.com/mylan-announce…

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on ... s.einnews.com/V8tQu54pey

Appeal board to review Sanofi’s Lantus insulin injection patents ift.tt/2zcp0Np #meddevice

Appeal board grants inter partes review of $SNY's Lantus insulin pen #patents in legal spat with $MYL. drugdeliverybusiness.com/appeal-board-r…

Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - Markets Insider bit.ly/2CgTnSi

Appeal board to review Sanofi’s Lantus #insulin injection patents. $SNY $MYL drugdeliverybusiness.com/appeal-board-r…

test Twitter Media - Appeal board to review Sanofi’s Lantus #insulin injection patents. $SNY $MYL https://t.co/ns3HdLSYl1 https://t.co/8YzvizscLd

Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - Markets Insider bit.ly/2o0dTDu

Mylan (MYL) Says PTAB Institutes Inter Partes Review Against Sanofi's Lantus Patents - StreetInsider.com dlvr.it/Q5wgnh

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

test Twitter Media - BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents https://t.co/mHjoELQVHT

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

test Twitter Media - BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents https://t.co/xt0THukYQ9

"BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents" ift.tt/2o2CtDL

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents reut.rs/2Cl7wy0 #BusinessNews #Companies

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on #mining minelistings.com/mine-news/myla…

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review… goo.gl/fb/hBx99U

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings #sovereignty sovereignmind.net/news/mylan-ann…

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents prn.to/2yscbuV

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims bit.ly/2ktjnld

Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - GuruFocus.com bit.ly/2AGAY42

Mylan Announces the US Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... - GuruFocus.com bit.ly/2AGbaoJ

Mylan Announces the US #Patent and #Trademark Appeal Board Institutes Inter Partes Review Proceedings on All ... #Patent prnewswire.com/news-releases/…

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims crweworld.com/article/news-p…

First Europe, now US: Insulin glargine (Lantus) worldwide under pressure, patent expirations in the US and introduction of Lilly's Basaglar #insulin #diabetes

@Kidfears99 @NeedInsulin @PhRMA I’ve been on insulin since however old you are in the fourth grade. I was on NPH and Regular to Lantus to Humalog. That’s why I’m still alive.

@poeticlibrarian @MTL613 I don't know why they had her on NPH, but we demanded to switch to Lantus at 1st follow up. Much better after that.

@MTL613 @nicki21n We were lucky that daughter was never on NPH. She was on Lantus & Humalog for about 1 mo, then pump #dsma

@DroopySocialwkr @sk1897 These people are spending their rent for their Lantus and their car payment for their Log and they get called “ noncompliant “ when they show up in DKA

@DroopySocialwkr @sk1897 I mostly work off the WalMart 4 dollar list and have for years. Some things though (albuterol) and you know how I feel about Lantus and HumaLog Quik pens

@hbrofman Some data re-specific drug net prices/cost-to-plan, e.g. Lantus is rebated around 75%. Also some transparency re: aggregate rebate amounts by therapeutic classes & gross revenue. Check SEC 8-K regarding separation of AR into AR trade and AR Pharma rebates: truth-out.org/news/item/4287…